The International Liver Congress in Amsterdam has officially wrapped up, but the energy and excitement around NASH – aka non-alcoholic steatohepatitis – persists.
Characterized by inflammation and scarring of the liver, NASH affects an estimated five percent or 15.9 million Americans. It comes as a progression of non-alcoholic fatty liver disease (NAFLD), believed to affect some 75-100 million people in the U.S. alone.